Eagle Rock Investment Company LLC Increases Stock Holdings in IQVIA Holdings Inc. $IQV

Eagle Rock Investment Company LLC increased its holdings in shares of IQVIA Holdings Inc. (NYSE:IQV) by 33.6% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 46,332 shares of the medical research company’s stock after buying an additional 11,657 shares during the quarter. IQVIA comprises approximately 1.3% of Eagle Rock Investment Company LLC’s portfolio, making the stock its 22nd biggest holding. Eagle Rock Investment Company LLC’s holdings in IQVIA were worth $8,800,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in IQV. Alliancebernstein L.P. lifted its holdings in shares of IQVIA by 0.6% during the 2nd quarter. Alliancebernstein L.P. now owns 3,555,929 shares of the medical research company’s stock worth $560,379,000 after acquiring an additional 19,573 shares during the period. Artisan Partners Limited Partnership purchased a new position in IQVIA during the second quarter worth approximately $515,772,000. JPMorgan Chase & Co. boosted its holdings in shares of IQVIA by 22.8% in the 2nd quarter. JPMorgan Chase & Co. now owns 3,126,171 shares of the medical research company’s stock valued at $492,659,000 after purchasing an additional 581,157 shares during the last quarter. Nordea Investment Management AB grew its stake in shares of IQVIA by 12.3% during the 3rd quarter. Nordea Investment Management AB now owns 2,314,219 shares of the medical research company’s stock valued at $421,257,000 after buying an additional 253,759 shares during the period. Finally, Cantillon Capital Management LLC increased its holdings in shares of IQVIA by 27.3% during the 3rd quarter. Cantillon Capital Management LLC now owns 1,926,934 shares of the medical research company’s stock worth $366,002,000 after buying an additional 413,256 shares during the last quarter. Hedge funds and other institutional investors own 89.62% of the company’s stock.

IQVIA Stock Down 1.3%

NYSE IQV opened at $166.70 on Monday. The company has a quick ratio of 0.70, a current ratio of 0.75 and a debt-to-equity ratio of 2.09. IQVIA Holdings Inc. has a fifty-two week low of $134.65 and a fifty-two week high of $247.04. The business has a 50 day moving average price of $223.12 and a two-hundred day moving average price of $209.19. The stock has a market cap of $28.39 billion, a PE ratio of 21.21, a P/E/G ratio of 1.61 and a beta of 1.37.

IQVIA (NYSE:IQV) last posted its quarterly earnings data on Thursday, February 5th. The medical research company reported $3.42 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.40 by $0.02. The company had revenue of $4.36 billion for the quarter, compared to analyst estimates of $4.24 billion. IQVIA had a net margin of 8.34% and a return on equity of 30.50%. The business’s quarterly revenue was up 10.3% on a year-over-year basis. During the same quarter last year, the firm posted $3.12 earnings per share. IQVIA has set its FY 2026 guidance at 12.550-12.850 EPS. As a group, sell-side analysts predict that IQVIA Holdings Inc. will post 10.84 EPS for the current fiscal year.

Analyst Ratings Changes

A number of research analysts recently weighed in on the company. Weiss Ratings reiterated a “hold (c)” rating on shares of IQVIA in a report on Thursday, January 22nd. Evercore ISI reaffirmed an “outperform” rating on shares of IQVIA in a research note on Thursday, February 5th. Robert W. Baird set a $258.00 target price on shares of IQVIA and gave the stock an “outperform” rating in a research report on Wednesday, October 29th. Wall Street Zen cut shares of IQVIA from a “buy” rating to a “hold” rating in a research report on Saturday, February 7th. Finally, JPMorgan Chase & Co. decreased their price objective on shares of IQVIA from $255.00 to $225.00 and set an “overweight” rating for the company in a research note on Friday, February 6th. Two research analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating and four have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $238.20.

About IQVIA

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.